Opendata, web and dolomites


Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Total Cost €


EC-Contrib. €






 ECRC project word cloud

Explore the words cloud of the ECRC project. It provides you a very rough idea of what is the project "ECRC" about.

evd    approval    nature    rvf    agree    advantage    humans    lot    public    standard    virus    cfp3    stage    protective    vaccine    rvfv    regulatory    priorities    launching    mechanism    chik    timing    align    stated    calls    ec    candidates    risk    afforded    risks    grant    mature    launched    efforts    lacking    relates    meet    list    inherently    correlates    2019    blueprint    investments    leverage    ebola    co    understand    urgency    incentives    unpredictable    sub    criteria    entities    remaining    feasible    2018    despite    quite    launch    vaccines    validation    rift    mid    health    promise    cfp3i    generating    aligned    pipeline    market    fda    encouraged    regulations    cfp    clinical    sga    protection    few    deemed    justified    identification    progression    interim    countries    award    structured    strengthen    duly    chikungunya    benefit    eligibility    cfp3ii    pathogens    mitigate    fever    gaps    ll    chikv    scope    accelerate    licensure    ema    efficacy    income    middle    proposals    context    january    outbreak    diseases    action    emergencies    cepi    valley    outbreaks    rapid   

Project "ECRC" data sheet

The following table provides information about the project.


Organization address
city: OSLO
postcode: 473
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Total cost 51˙428˙572 €
 EC max contribution 36˙000˙000 € (70%)
 Programme 1. H2020-EU.3.1.2. (Preventing disease)
 Code Call H2020-SGA-SC1-CEPI-2019
 Funding Scheme SGA-CSA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-08-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

The objective of this specific grant agreement (SGA) is to leverage co-funding from the European Commission to accelerate the development of vaccines against Rift Valley Fever (RVF), Chikungunya (CHIK) and Ebola virus diseases (EVD).

• RVF and CHIK vaccine development will be addressed by CEPI’s third Call for Proposals (CFP3), and it will structured through launching two sub-calls; CFP3i and CFP3ii. This SGA only relates to CFP3i, and has the following objectives: a) For RVFV vaccines, to support clinical testing or activities enabling clinical Phase l/ll testing of the most advanced RVFV candidates, including identification of correlates of protection and their validation, which can facilitate future regulatory approval. b) For CHIKV vaccines, to support the rapid progression of the most advanced clinical CHIKV vaccine candidates through mid-stage and late-stage clinical development, and to support activities enabling future efficacy testing, including identification of correlates of protection and their validation that can facilitate future regulatory approval. The call will be launched January 2019 and will be open to all entities that meet the eligibility criteria and agree to CEPI’s award conditions – which are aligned with EU regulations.

EVD vaccine development will focus on addressing the remaining evidence gaps towards the licensure by FDA and/or EMA of the leading vaccine candidates, particularly on generating evidence of the protective efficacy of the vaccines in humans in the context of an outbreak. Towards this scope, and in order to take advantage of the research opportunities afforded by any large-scale Ebola outbreak, CEPI is expected to facilitate the rapid launch of clinical studies of the lead Ebola vaccine candidates. If feasible, the standard CfP mechanism will be used. However, in duly justified emergencies CEPI may award a grant without a call for proposals.

RVF and EVD are included among the WHO R&D Blueprint list of priority pathogens in 2018, while CHIKV was deemed to present a major public health risks for which “further research and development is needed” and “efforts in the interim to understand and mitigate them are encouraged”. Despite this stated urgency, action has been lacking – in part because low and middle-income countries are most at risk for future outbreaks and market incentives are lacking, both due to this and the inherently unpredictable nature and timing of future outbreaks. The current pipeline of candidates for these three pathogens does however bring a lot of promise; since there are quite a few mature candidates in the pipeline, targeted investments from CEPI and the EC could bring significant benefit and further strengthen and align the two entities’ existing priorities in vaccine development.


List of deliverables.
Opening of call online Documents, reports 2020-02-12 15:34:46
Project description template Documents, reports 2020-02-12 15:34:36

Take a look to the deliverables list in detail:  detailed list of ECRC deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ECRC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ECRC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.2.)

ECRC (2019)

Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Read More  

EMPOWER (2020)

European platforM to PromOte Wellbeing and HEalth in the woRkplace

Read More  


Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response.

Read More